{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:14:03Z","timestamp":1787318043234,"version":"build-2736575974"},"reference-count":23,"publisher":"Elsevier BV","issue":"42","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,8]],"date-time":"2022-09-08T00:00:00Z","timestamp":1662595200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.vaccine.2022.09.012","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T05:46:13Z","timestamp":1663047973000},"page":"6004-6011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies"],"prefix":"10.1016","volume":"40","author":[{"given":"Atsushi","family":"Yamanaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pimploy","family":"Rattanaamnuaychai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mami","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryosuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiharu","family":"Matsuura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Konishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2022.09.012_b0005","series-title":"Fields virology","first-page":"747","article-title":"Flaviviruses","author":"Pierson","year":"2013"},{"key":"10.1016\/j.vaccine.2022.09.012_b0010","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1016\/j.vaccine.2014.01.040","article-title":"A review of successful flavivirus vaccines and the problems with those flaviviruses for which vaccines are not yet available","volume":"32","author":"Ishikawa","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.012_b0015","unstructured":"World Health Organization. Dengue vaccine: WHO position paper \u2013 September 2018. Weekly Epidemiological Record 93 (2018) 457\u2013476. Available from: <https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/274315\/WER9336.pdf?ua=1> [accessed 13 July 2021]."},{"key":"10.1016\/j.vaccine.2022.09.012_b0020","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/265739a0","article-title":"Antibody-enhanced dengue virus infection in primate leukocytes","volume":"265","author":"Halstead","year":"1977","journal-title":"Nature"},{"issue":"6334","key":"10.1016\/j.vaccine.2022.09.012_b0025","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1126\/science.aal4365","article-title":"Enhancement of Zika virus pathogenesis by preexisting antiflavivirus immunity","volume":"356","author":"Bardina","year":"2017","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.vaccine.2022.09.012_b0030","doi-asserted-by":"crossref","first-page":"e1007640","DOI":"10.1371\/journal.ppat.1007640","article-title":"The possible role of cross-reactive dengue virus antibodies in Zika virus pathogenesis","volume":"15","author":"Langerak","year":"2019","journal-title":"PLoS Pathog"},{"issue":"6507","key":"10.1016\/j.vaccine.2022.09.012_b0035","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1126\/science.abb6143","article-title":"Zika virus infection enhances future risk of severe dengue disease","volume":"369","author":"Katzelnick","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2022.09.012_b0040","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.vaccine.2008.10.087","article-title":"Vaccine-induced enhancement of viral infections","volume":"27","author":"Huisman","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.012_b0045","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.isci.2019.02.012","article-title":"Key amino acid substitution for infection-enhancing activity-free designer dengue vaccines","volume":"13","author":"Yamanaka","year":"2019","journal-title":"iScience"},{"key":"10.1016\/j.vaccine.2022.09.012_b0050","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3389\/fimmu.2012.00334","article-title":"Sculpting humoral immunity through dengue vaccination to enhance protective immunity","volume":"3","author":"Crill","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.vaccine.2022.09.012_b0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.15252\/embr.201745302","article-title":"The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design","volume":"19","author":"Rey","year":"2018","journal-title":"EMBO Rep"},{"key":"10.1016\/j.vaccine.2022.09.012_b0060","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1128\/JVI.75.5.2204-2212.2001","article-title":"Generation and characterization of a mammalian cell line continuously expressing Japanese encephalitis virus subviral particles","volume":"75","author":"Konishi","year":"2001","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2022.09.012_b0065","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/j.micinf.2007.05.013","article-title":"Co-immunization with West Nile DNA and inactivated vaccines provides synergistic increases in their immunogenicities in mice","volume":"9","author":"Ishikawa","year":"2007","journal-title":"Microbes Infect"},{"key":"10.1016\/j.vaccine.2022.09.012_b0070","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jviromet.2017.02.011","article-title":"Utility of Japanese encephalitis virus subgenomic replicon-based single-round infectious particles as antigens in neutralization tests for Zika virus and three other flaviviruses","volume":"243","author":"Yamanaka","year":"2017","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2022.09.012_b0075","doi-asserted-by":"crossref","unstructured":"Yamanaka A, Matsuda M, Okabayashi T, Pitaksajjakul P, Ramasoota P, Saito K, et al. Seroprevalence of flavivirus neutralizing antibodies in Thailand by high-throughput neutralization assay: endemic circulation of Zika virus before 2012. mSphere 2021;6:e0033921. doi: 10.1128\/mSphere.00339-21.","DOI":"10.1128\/mSphere.00339-21"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.012_b0080","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-34865-y","article-title":"High-throughput neutralization assay for multiple flaviviruses based on single-round infectious particles using dengue virus type 1 reporter replicon","volume":"8","author":"Matsuda","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2022.09.012_b0085","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jviromet.2009.10.026","article-title":"A simple assay system for infection-enhancing and -neutralizing antibodies to dengue type 2 virus using layers of semi-adherent K562 cells","volume":"163","author":"Konishi","year":"2010","journal-title":"J Virol Methods"},{"key":"10.1016\/j.vaccine.2022.09.012_b0090","doi-asserted-by":"crossref","first-page":"6449","DOI":"10.1016\/j.vaccine.2016.11.021","article-title":"Complement-independent dengue virus type 1 infection-enhancing antibody reduces complement-dependent and -independent neutralizing antibody activity","volume":"34","author":"Yamanaka","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2022.09.012_b0095","doi-asserted-by":"crossref","first-page":"579","DOI":"10.7883\/yoken.JJID.2016.379","article-title":"Dengue-immune humans have higher levels of complement-independent enhancing antibody than complement-dependent neutralizing antibody","volume":"70","author":"Yamanaka","year":"2017","journal-title":"Jpn J Infect Dis"},{"key":"10.1016\/j.vaccine.2022.09.012_b0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.3390\/v12080892","article-title":"FLAVi: an enhanced annotator for viral genomes of flaviviridae","volume":"12","author":"de Bernadi","year":"2020","journal-title":"Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2022.09.012_b0105","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","article-title":"Modified mRNA vaccines protect against Zika virus infection","volume":"168","author":"Richner","year":"2017","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.vaccine.2022.09.012_b0110","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","article-title":"A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection","volume":"20","author":"Slon-Campos","year":"2019","journal-title":"Nat Immunol"},{"issue":"1","key":"10.1016\/j.vaccine.2022.09.012_b0115","doi-asserted-by":"crossref","DOI":"10.1186\/s12879-016-1873-8","article-title":"Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults","volume":"16","author":"Saito","year":"2016","journal-title":"BMC Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X22011100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:19:01Z","timestamp":1759403941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X22011100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":23,"journal-issue":{"issue":"42","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S0264410X22011100"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.012","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineered flavivirus vaccines control induction of crossreactive infection-enhancing and -neutralizing antibodies","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2022.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}